Digital mental health technologies โ€“ a valuable tool in supporting people with depression and anxiety

January 29, 2026
Medical Communications MHRA, NHS, NICE, Wellcome, digital technologies, medical communications, mental health

The potential benefits of digital mental health technology for managing depression, anxiety and stress, together with other forms of care, …

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026
Research and Development Barts Health NHS Trust, H.I.G. Realty, health innovation

Barts Health NHS Trust and H.I.G. Realty have announced a collaboration to launch an applied healthcare innovation building in the …

Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US

January 29, 2026
Head of Business Development US, Rentschler Biopharma

Rentschler Biopharma has announced the appointment of Detra Glinatsis as Head of Business Development US. Glinatsis brings more than two …

Five Facts about spinal muscular atrophy

January 28, 2026
Medical Communications Five Facts, Neurology, early diagnosis, five types, gene therapy, muscle weakness, spinal muscular atrophy

1 Spinal muscular atrophy (SMA) is a genetic disease involving the loss of motor neurons in the spinal cord.1 Its …

Sobiโ€™s Aspaveli receives European Commission approval for treatment of two rare kidney diseases

January 28, 2026
Aspaveli, European Commission, Nephrology, sobi

Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) for the treatment of two …

Everdrone appoints David Borkmann as Senior Medical Advisor

January 28, 2026
Everdrone, senior medical advisor

Everdrone, a provider of autonomous drone systems for use in healthcare and emergency response, has announced the appointment of David …

MRM Healthโ€™s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026
FDA, Gastrointestinal tract, MRM Health, ulcerative colitis

Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational New Drug (IND) clearance from …

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026
Crystalys Therapeutics, chief financial officer

Crystalys Therapeutics has announced the appointment of Justin Thacker as Chief Financial Officer (CFO). Thacker has spent over 20 years …

Rentschler Biopharma appoints Uwe Buecheler as interim CEO

January 26, 2026
Rentschler Biopharma, interim CEO

Rentschler Biopharma, a contract development and manufacturing organisation (CDMO) specialising in biopharmaceutical products, has announced the appointment of Uwe Buecheler …

Sandozโ€™ Ondibta receives European Commission approval for diabetes

January 26, 2026
Research and Development Diabetes, Ondibta, Sandoz

Sandoz has announced that its Ondibta (insulin glargine) has received approval from the European Commission (EC) for the treatment of …

Complement Therapeuticsโ€™ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026
Research and Development Complement Therapeutics, FDA, Opthalmology, geographic atrophy

Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), …

PSI appoints David Allen as Country Manager for Canada

January 22, 2026
Country Manager for Canada, PSI

PSI, a contract research organisation (CRO) with a focus on clinical trial delivery, has announced the appointment of David Allen …

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026
Qureight, chief medical officer

Qureight has announced the appointment of Dr Steven Bishop as its new Chief Medical Officer (CMO). Bishop previously held the …

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026
Research and Development Iktos, Oncology, Pierre Fabre Laboratories

Pierre Fabre Laboratories and Iktos have announced a new collaboration intended to discover and develop new small-molecule drug candidates for …

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026
Qureight, chief operating officer

Qureight has announced the appointment of Rebecca Simmons as Chief Operating Officer (COO). Simmons brings more than two decades of …

European Medicines Agency recommended 104 medicines for approval in 2025

January 20, 2026
Research and Development European Medicines Agency, Rare Diseases

The European Medicines Agency (EMA) has announced data from 2025 showing that over the course of the year it recommended …

Spike in searches relating to spinal muscular atrophy following Jesy Nelson disclosure

January 19, 2026
Medical Education Neurology, spinal muscular atrophy

New research from the Centre for Surgery has shown a significant rise in Google searches relating to spinal muscular atrophy …

Biogenโ€™s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy

January 19, 2026
Research and Development Biogen, Neurology, Spinraza, spinal muscular atrophy

Biogenโ€™s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose regimen for the treatment of …

Alto Neuroscience announces new patent for depression treatment

January 15, 2026
Sales and Marketing Alto Neuroscience, Psychiatry, depression

Alto Neuroscience, a clinical-stage biopharmaceutical company specialising in precision treatments for neuropsychiatric conditions, has announced the issuance of a US …

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

January 15, 2026
Sales and Marketing Arkin Capital, biotech

Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed to invest in pre-clinical and …

The Gateway to Local Adoption Series

Latest content